Skip to main content
AB Science logo

AB Science — Investor Relations & Filings

Ticker · AB ISIN · FR0010557264 LEI · 969500U43TVR8CCVBJ97 PA Manufacturing
Open in API
Filings indexed 742 across all filing types
Latest filing 2014-02-14 Earnings Release
Country FR France
Listing PA AB

About AB Science

https://www.ab-science.com

AB Science is a clinical-stage pharmaceutical company that researches, develops, and markets protein kinase inhibitors for human and veterinary medicine. The company focuses on developing innovative drugs for diseases with high unmet medical needs. Its pipeline is centered on two main compounds: masitinib and AB8939. Masitinib, a highly selective tyrosine kinase inhibitor, is under investigation for treating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, as well as inflammatory diseases like mastocytosis. AB8939 is a microtubule destabilizer being developed for oncology, specifically for Acute Myeloid Leukemia (AML). The company also commercializes masitinib in veterinary medicine under the brand name Masivet®.

Recent filings

Filing Released Lang Actions
AB Science FR
Earnings Release Classification · 98% confidence The document is titled "Information trimestrielle – Quatrième trimestre 2013" (Quarterly Information – Fourth Quarter 2013) and reports key financial figures (revenue, cash position) for the quarter ending December 31, 2013, along with clinical development updates. This structure—a focused release of financial highlights for a specific shorter period (quarterly)—is characteristic of an Earnings Release (ER). It is not the comprehensive Annual Report (10-K) nor a full transcript (CT). Since it provides the initial announcement of results, ER is the most appropriate classification. Q4 2013
2014-02-14 French
AB Science EN
Earnings Release Classification · 99% confidence The document is dated February 14, 2014, and reports revenues for the fourth quarter and year-to-date as of December 31, 2013. It provides key financial highlights (€1,933 thousand turnover, €31.9 million cash reserves) and an update on clinical development activities. This structure—a brief announcement of period-end financial results and operational updates—is characteristic of an Earnings Release (ER). It is not a comprehensive annual report (10-K) or a detailed interim report (IR), nor is it merely an announcement of a report (RPA). Q4 2013
2014-02-14 English
AB Science EN
Regulatory Filings Classification · 95% confidence The document is an announcement from AB Science regarding a negative opinion adopted by the CHMP (Committee for Medicinal Products for Human Use) of the EMA concerning the conditional approval of Masitinib for pancreatic cancer. The company explicitly states its intention to appeal this decision. This content relates to regulatory outcomes, legal/procedural challenges against regulatory bodies, and significant developments in drug approval status. While it touches upon clinical trial results, its primary function is to report a specific regulatory action and the company's response (appeal). This fits best under 'Legal Proceedings Report' (LTR) as it details a formal dispute/challenge against a regulatory decision, or potentially 'Regulatory Filings' (RNS) as a general announcement of a significant regulatory event. Given the focus on the appeal process against a regulatory body's decision, LTR is a strong candidate, but since it's a direct announcement about a regulatory outcome and subsequent legal/procedural step (appeal), and not a lawsuit against a third party, 'Regulatory Filings' (RNS) serves as a robust general category for significant, non-standard regulatory updates that don't fit other specific financial categories like ER or 10-K. However, the nature of challenging a regulatory opinion is very close to reporting on a legal/procedural matter. Since there is no specific 'Regulatory Challenge' code, and it is a formal communication about a regulatory process outcome, RNS is the most appropriate general regulatory announcement category.
2014-01-23 English
AB Science FR
Regulatory Filings Classification · 95% confidence The document is an announcement from AB Science dated January 23, 2014, detailing a negative opinion from the CHMP (Committee for Human Medicinal Products) of the EMA regarding the conditional marketing authorization for masitinib for pancreatic cancer. It discusses the reasons for the negative opinion (insufficient results in the general population, toxicity concerns, quality issues) and the company's intention to appeal. This content relates to regulatory and legal proceedings concerning a drug application, specifically addressing the outcome of a regulatory review and the subsequent legal/appeal process. This fits best under 'Legal Proceedings Report' (LTR) as it concerns regulatory action/decision and the company's response to challenge that decision, which is a form of legal/regulatory dispute. It is not a general earnings release (ER), a full annual report (10-K), or a general regulatory filing (RNS), but a specific update on a significant regulatory hurdle and appeal plan.
2014-01-23 French
AB Science
Share Issue/Capital Change Classification · 95% confidence The document is titled "INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL SOCIAL" (Monthly Information Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital). It explicitly references Article 221-1 and 223-16 of the AMF (Autorité des Marchés Financiers) General Regulation. It provides a table showing the total number of shares and voting rights as of a specific date (November 30, 2013). This content directly relates to the official reporting of share capital structure and voting rights, which is a specific regulatory disclosure. While it is a monthly report, none of the primary codes (10-K, IR, ER) fit perfectly. The closest fit among the provided definitions that deals with share structure/voting rights is not explicitly listed, but the nature of reporting voting rights and share capital changes often falls under general regulatory disclosures or specific capital change notifications. However, given the structure and content (monthly update on voting rights/shares), it is a specific regulatory filing. Since there is no dedicated 'Voting Rights/Share Capital Monthly Update' code, I must evaluate the existing options. It is not a Director's Dealing (DIRS), Major Shareholding Notification (MRQ), or Share Issue (SHA). It is a mandatory regulatory disclosure. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for mandatory, non-financial periodic disclosures that don't fit elsewhere. However, let's re-examine the definitions. The document is a formal disclosure about the total number of voting rights and shares. This is a very specific type of regulatory filing. If we look closely at the definitions, 'Declaration of Voting Results & Voting Rights Announcements' (DVA) is for results *from* a meeting. This is a periodic statement of the total rights. Given the lack of a perfect fit, RNS is the fallback. But, if we consider the closest thematic fit, it relates to the structure of ownership/voting rights. Since it is a formal, periodic regulatory disclosure mandated by the AMF, RNS is the safest classification as a general regulatory filing.
2013-12-05 French
AB Science EN
Investor Presentation Classification · 95% confidence The document announces the initiation of a Phase 3 study for the drug masitinib in metastatic colorectal cancer. It details the study design, references preliminary Phase 2 results, and discusses the mechanism of action and market incidence. This type of announcement, focusing on clinical trial progress and scientific updates rather than routine financial reporting (like 10-K, ER, or IR), is best classified as an Investor Presentation (IP) or a general regulatory/corporate update. Since it is a detailed scientific/clinical update aimed at investors and stakeholders, 'Investor Presentation' (IP) is the most fitting category, although it could also be considered a Regulatory Filing (RNS) if it were a mandatory disclosure. Given the depth of clinical detail, IP is preferred over the generic RNS. It is not a Call Transcript (CT), Earnings Release (ER), or a formal financial report (10-K, IR).
2013-12-02 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.